Windlas Biotech Ltd
WINDLASWindlas Biotech Ltd
WINDLAS
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 37.82 | 5.01 | 0.51% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
The company provides pharmaceutical development services. It provides contract manufacturing services for pharmaceutical industrialists and also focuses on product development and manufacturing capabilities in generic products.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 356.54 | 361.07 | 331.34 | 436.34 | 472.64 | 523.05 | 644.43 | 676.31 | ||||||||
Raw Materials | 234.55 | 188.27 | 224.35 | 270.74 | 307.56 | 340.71 | 386.59 | 579.42 | ||||||||
| Power & Fuel Cost | 7.29 | 7.28 | 8.04 | 11.53 | 11.01 | 12.90 | 16.15 | |||||||||
| Employee Cost | 44.54 | 42.96 | 43.57 | 58.32 | 63.41 | 70.32 | 87.46 | |||||||||
| Selling & Administrative Expenses | 13.80 | 18.29 | 16.25 | 15.09 | 23.55 | 30.15 | 35.89 | |||||||||
| Operating & Other expenses | 12.69 | 12.72 | 2.65 | 44.67 | 7.98 | -1.23 | 26.70 | |||||||||
EBITDA | 43.67 | 91.55 | 36.48 | 35.99 | 59.13 | 70.20 | 91.64 | 96.89 | ||||||||
| Depreciation/Amortization | 17.35 | 10.59 | 9.29 | 12.97 | 12.15 | 12.36 | 13.44 | 16.47 | ||||||||
| PBIT | 26.32 | 80.96 | 27.19 | 23.02 | 46.98 | 57.84 | 78.20 | 80.42 | ||||||||
| Interest & Other Items | 6.47 | 4.84 | 2.53 | 1.29 | 1.42 | 0.79 | 1.11 | 1.37 | ||||||||
| PBT | 19.85 | 76.12 | 24.66 | 21.73 | 45.56 | 57.05 | 77.09 | 79.05 | ||||||||
| Taxes & Other Items | 8.65 | 12.30 | 8.45 | 5.91 | 7.47 | 14.41 | 18.91 | 19.46 | ||||||||
| Net Income | 11.20 | 63.82 | 16.21 | 15.82 | 38.09 | 42.64 | 58.18 | 59.59 | ||||||||
| EPS | 14.11 | 74.91 | 17.81 | 17.38 | 24.66 | 19.96 | 27.89 | 28.65 | ||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 3.50 | 4.00 | 5.50 | 4.00 | ||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.20 | 0.20 | 0.14 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Windlas Biotech Ltd | 38.74 | 5.01 | 0.51% |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare WINDLAS with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Decreased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has decreased by 1.13%
Top 4 Mutual Funds holding Windlas Biotech Ltd
| Funds (Top 4) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.0396% | Percentage of the fund’s portfolio invested in the stock 1.44% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 22/48 (-2) |
ICICI Prudential Smallcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.9463% | Percentage of the fund’s portfolio invested in the stock 0.52% | Change in the portfolio weight of the stock over the last 3 months -0.14% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 40/117 (-2) |
UTI Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8294% | Percentage of the fund’s portfolio invested in the stock 1.65% | Change in the portfolio weight of the stock over the last 3 months 0.31% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 23/45 (+4) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 17, 2024
Dividend/Share
₹5.50
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 5, 2023
Dividend/Share
₹4.00
Ex DateEx Date
Sep 5, 2023
Cash Dividend
Ex DateEx DateSep 9, 2022
Dividend/Share
₹3.50
Ex DateEx Date
Sep 9, 2022
Windlas Biotech will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
Windlas Biotech announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live
Windlas Biotech announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live
Net profit of Windlas Biotech rose 11.68% to Rs 13.48 crore in the quarter ended June 2024 as against Rs 12.07 crore during the previous quarter ended June 2023. Sales rose 20.97% to Rs 175.15 crore in the quarter ended June 2024 as against Rs 144.79 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales175.15144.79 21 OPM %11.9211.84 - PBDT24.5219.53 26 PBT18.3116.34 12 NP13.4812.07 12 Powered by Capital Market - Live
Windlas Biotech will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Windlas Biotech consolidated net profit rises 10.59% in the December 2022 quarter
Starlit Power Systems Ltd leads losers in ‘B’ group
Windlas Biotech posts single-digit growth numbers in Q1FY23; stock slips ~2%
Stocks in Focus on May 13: TaMo, L&T, SBI, Eicher Motors, Windlas Biotech & More
Windlas Biotech consolidated net profit rises 150.68% in the March 2022 quarter
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 12.28%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.16% to 0.17%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -1.83%, vs industry avg of 15.28%